CA Patent

CA2792646A1 — Improved uses and compositions for safe and effective treatment of erythema

Assigned to Galderma Research and Development SNC · Expires 2011-09-29 · 15y expired

What this patent protects

Improved methods and compositions for safe and effective treatment of erythemaora symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight ofbrim…

USPTO Abstract

Improved methods and compositions for safe and effective treatment of erythemaora symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight ofbrimonidine and a pharmaceutically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
CA2792646A1
Jurisdiction
CA
Classification
—
Expires
2011-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Galderma Research and Development SNC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.